Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-05
2009-11-10
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S268100, C546S268400, C546S271100, C548S206000, C548S207000, C548S212000, C514S337000, C514S338000, C514S372000
Reexamination Certificate
active
07615570
ABSTRACT:
Compounds having formula (I)or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein L, A, G, R1, R2and R3are as defined herein. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence.
REFERENCES:
patent: 4147698 (1979-04-01), Wade et al.
patent: 4166910 (1979-09-01), Wade et al.
patent: 4743692 (1988-05-01), Teller et al.
patent: 2004/108133 (2004-12-01), None
patent: 2005/009982 (2005-02-01), None
Teller et al (1988): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 1988:492994.
Blum et al (2005): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2005:99489.
Berge, S.M., et al., “Pharmaceutical Salts”,J. Pharmaceutical Sciences, 66(1):1-17 (1977).
Caterina, M.J. and Julius, D., “The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway”,Annu. Rev. Neurosci., 24:487-517 (2001).
Caterina, et al., “The capsaicin receptor: a heat-activated ion channel in the pain pathway”,Nature, 389:816-824 (1997).
Caterina, et al., “Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor”,Science, 288:306-313 (2000).
Collier, et al., “The Abdominal Constriction Response and Its Suppression by Analgesic Drugs in the Mouse”,Br. J. Pharmacol. Chemother., 32:295-310 (1968).
Davis, et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia”,Nature, 405:183-187 (2000).
Fowler, “Intravesical Treatment of Overactive Bladder”,Urology, 55:60-64 (2000).
Hartwig, J., et al., “Recent advances in palladium- and nickel- catalyzed chemistry provide new ways to construct C-N and C-) bonds”,Angew. Chem. Int. Ed., 37:2046-2067 (1998).
Kiyomori, A., et al., “An Efficient Copper-Catalyzed Coupling of Aryl Halides with Imidazoles”,Tet. Lett., 40:2657-2640 (1999).
Klapars, A., et al., “A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and theN-Arylation of Nitrogen Heterocycles”,J. Amer. Chem. Soc., 123:7727-7729 (2001).
Knochel, P. and Singer, R.D., “Preparation and Reactions of Polyfunctional Organozinc Reagents in Organic Synthesis”,Chem. Rev., 93:2117-2188 (1993).
Kwong, F.Y., et al., “Copper-Catalyzed Coupling of Alkylamines and Aryl Iodides: An Efficient System Even in an Air Atmosphere”, Org. Lett., 4:581-584 (2002).
Nolano, et al., Pain, “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation”, 81:135,145 (1999).
Pircio, et al., “A New Method for the Evaluation of Analgesic Activity Using Adjuvant-Induced Arthritis in the Rat”, Eur. J Pharmacol. , vol. 31(2), pp. 207-215(1975).
Sugahara, M., et al., “A Facile Copper-Catalyzed Ullmann Condensation:N-Arylation of Heterocyclic Compounds Containing an —NHCO- Moiety”,Chem. Pharm. Bull., 45: 719-721 (1997).
Wolfe, J.P., et al., “Rational Development of Practical Catalysts for Aromatic Carbon-Nitrogen Bond Formation”,Acc. Chem. Res., 13:805-818 (1998).
Wolfe, J.P., et al., “Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates”,J. Org. Chem., 65:1158-1174 (2000).
Yang, B.H., et al., “Palladium-catalyzed amination of aryl halides and sulfonates”,J. Organomet, Chem., 576:125-146 (1999).
Brown Brian S.
Jinkerson Tammie K.
Keddy Ryan G.
Lee Chih-Hung
Abbott Laboratories
Shameem Golam M
Srivastava Sonali S.
LandOfFree
Antagonists to the vanilloid receptor subtype 1 (VR1) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists to the vanilloid receptor subtype 1 (VR1) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists to the vanilloid receptor subtype 1 (VR1) and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114395